This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Imbruvica
  • /
  • Study of the Bruton's Tyrosine Kinase (BTK) Inhibi...
Clinical trial

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Read time: 1 mins
Last updated:1st Aug 2014

The purpose of this study is to evaluate overall response rate (ORR) (complete response [CR] rate plus partial response [PR] rate) of ibrutinib (IMBRUVICA™; PCI-32765; JNJ-54179060), as assessed by an Independent Review Committee (IRC), in participants with relapsed or refractory mantle cell lymphoma (MCL-a cancer of the lymph nodes or tissues).


Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Enrollment: 16
Study Start Date: August 2014
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Ibrutinib

Category Value
Study start date 2014-08-01

View full details